

LITERATURA

1. Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. *Annals of the Rheumatic Diseases* Published Online First. 2022. doi: 10.1136/ard-2022-223296.
2. Urbánek K. Infliximab. *Interní Med.* 2017;19(1):42-46.
3. www.sukl.cz.
4. Korsten P, Strohmayer K, Baughman RP, Sweiss NJ. Refractory pulmonary sarcoidosis – proposal of a definition and recommendations for the diagnostic and therapeutic approach. *Clin Pulm Med.* 2016;23(2):67-75.
5. Ingram JR, Woo PN, Chua SL, et al. Interventions for hidradenitis suppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence quality. *Br J Dermatol.* 2016;174(5):970-978.
6. Schwartzman S. Advancements in the management of uveitis. *Best Pract Res Clin Rheumatol.* 2016;30(2):304-315.
7. Westhovens R, Wiland P, Zawadzki M, et al. Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial. *Rheumatology (Oxford).* 2021;60(5):2277-2287. doi: 10.1093.
8. Schreiber S, Ben-Horin S, Leszczyszyn J, et al. Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease. *Gastroenterology.* 2021;160(7):2340-2353. doi: 10.1053.

23. ČESKÁ KONFERENCE KLINICKÉ FARMAKOLOGIE

7.–9. září 2023

 Teoretické ústavy
LF UP v Olomouci
